BriaCell Therapeutics Corp. (TSX:BCT)
Canada · Delayed Price · Currency is CAD | Market Cap | 33.06M +23.4% |
| Revenue (ttm) | n/a |
| Net Income | -41.76M |
| EPS | -13.15 |
| Shares Out | 8.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,225 |
| Open | 4.010 |
| Previous Close | 3.800 |
| Day's Range | 3.890 - 4.010 |
| 52-Week Range | 3.680 - 44.100 |
| Beta | 1.64 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About BriaCell Therapeutics
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore Co... [Read more]
News
BriaCell Therapeutics Announces Closing of Offering
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotec...
BriaCell Presents Positive Clinical Data at ASCO 2026
Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3 TWiST analysis,...
BriaCell Therapeutics Announces Pricing of Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biote...
BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board
BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board
BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study
BriaCell (BCTX) Therapeutics announces that the independent Data Safety Monitoring Board, DSMB, has issued its sixth consecutive positive recommendation following review of safety data from BriaCell’s...
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...
BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026
BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026
BriaCell announces data from Bria-IMT at ASCO 2026
BriaCell (BCTX) Therapeutics announces clinical data from three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 202...
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
PHILADELPHIA and VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancer Bria-OVA+, BriaCell's next generation personalized immunotherapy candidate for ovarian cancer,...
BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment
BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...
BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment
BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment
BriaCell adds Penn Medicine as Phase 3 breast cancer study site
BriaCell (BCTX) Therapeutics has added Penn Medicine’s Abramson Cancer Center as a clinical trial site in its ongoing pivotal Phase 3 study evaluating Bria-IMT in combination with an immune checkpoint...
BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...
BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...
BriaCell receives FDA clearance to initiate Bria-BRES+ trial
BriaCell (BCTX) T has received FDA clearance to initiate clinical evaluation of Bria-BRES+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for metastatic breast cancer.
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancer Bria-BRES+ is BriaCell's next generation persona...
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...
BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting
BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting
BriaCell presents anti-cancer activity of Bria-OTS
BriaCell (BCTX) Therapeutics is presenting “positive” data from its preclinical Bria-OTS+ platform at the 2026 American Association for Cancer Research, AACR, Annual Meeting taking place April 17-22 a...
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
PHILADELPHIA and VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...
BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting
BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting
BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR
BriaCell (BCTX) Therapeutics announces that it is presenting positive data in three clinical posters at the 2026 American Association for Cancer Research, AACR, Annual Meeting, taking place April 17-2...